Details:
Tiziana intends to use the net proceeds to advance the clinical development of Foralumab, to initiate a trial in HCC patients with Milciclib, to expedite clinical development of TZLS-501 for coronavirus COVID-19, and for working capital and other general corporate purposes
Lead Product(s): Foralumab
Therapeutic Area: Gastroenterology Product Name: TZLS-401
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $57.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 05, 2020